带状疱疹抗病毒药物阿昔洛韦临床应用评价

The Clinical Application Evaluation of Antiviral Drug Acyclovir in the Treatment of Herpes Zoster

目的:分析静脉阿昔洛韦在带状疱疹治疗中的临床价值。方法:选取2011年2月-2013年12月在笔者所在医院治疗的129例带状疱疹患者,按照随机数字表法将其分为静脉阿昔洛韦组65例和口服阿昔洛韦组64例,观察比较两组患者的临床疗效、疼痛缓解时间、疱止时间、结痂时间、50%皮损结痂时间、皮损消退时间、VAS评分。结果:经治疗后,静脉阿昔洛韦组的治疗总有效率92.31%(60/65)明显高于口服阿昔洛韦组的73.44%(47/64),疼痛缓解时间、疱止时间、结痂时间、50%皮损结痂时间、皮损消退时间均明显短于口服阿昔洛韦组,VAS评分明显低于口服阿昔洛韦组,差异均有统计学意义(P<0.05)。结论:静脉注射阿昔洛韦能够有效地治疗带状疱疹,控制带状疱疹神经痛,值得临床推广应用。

Objective：To analyze the clinical value of intravenous Acyclovir in the treatment of herpes zoster.Method：129 patients with herpes zoster admitted to our hospital from February 2011 to December 2013 were selected,they were divided into the intravenous Acyclovir group for 65 cases and the oral Acyclovir group for 64 cases.The clinical effect,pain relief time,blister stop time,scabby time,50% lesions scabby time,skin fade time and VAS score between the two groups were observed and compared.Result：The total effective rate of intravenous Acyclovir group was 92.31%（60/65）,it was significantly higher than 73.44%（47/64） of oral Acyclovir group,the pain relief time,blister stop time,scabby time,50% lesions scabby time,skin fade time in intravenous Acyclovir group were significantly shorter than those of oral Acyclovir group,the VAS score of intravenous Acyclovir group was significantly lower than oral Acyclovir group,the differences were statistically significant（P〈0.05）.Conclusion：Intravenous Acyclovir can effectively treat herpes zoster and control herpes zoster neuralgia,is worthy of clinical application.